On Drug Price Increases, Pfizer's Read Expects ‘Business As Normal’ In 2019

Presiding over his last earnings call as the CEO of Pfizer, Ian Read was pressed about the company's drug pricing strategy for 2019 amid push back from the Trump Administration.

 Ladder made of coins with colorful pills on top suggesting the growing prices of medicine or drugs

Pfizer Inc. CEO Ian Read suggested the company isn't going to back off its customary January price increases, even with ongoing pressure coming from the Trump Administration. Read was pressed by analysts during the company's third quarter earnings call Oct. 30 about expectations for the annual drug price increases that are generally taken at the beginning of the year.

"I expect our approach by the end of the year will be what I would characterize as business as normal,"...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access